Abstract: TH-PO031
Galectin-3 and EGF Are the Only Cardiorenal Biomarkers to Predict AKI Progression in the Setting of Acute Heart Failure
Session Information
- AKI: Biomarkers, Risk Factors, Treatments, Outcomes
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 102 AKI: Clinical‚ Outcomes‚ and Trials
Authors
- Duff, Stephen, University College Dublin College of Health Sciences, Dublin, Ireland
- Wettersten, Nicholas, VA San Diego Healthcare System, San Diego, California, United States
- Horiuchi, Yu, Shakai Fukushi Hojin Mitsui Kinen Byoin, Chiyoda-ku, Tokyo, Japan
- Raturi, Sagar, University College Dublin College of Health Sciences, Dublin, Ireland
- Irwin, Ruairi, University College Dublin College of Health Sciences, Dublin, Ireland
- Murray, Patrick T., University College Dublin College of Health Sciences, Dublin, Ireland
Group or Team Name
- The AKINESIS Investigators
Background
Acute Kidney Injury (AKI) is common in hospitalized patients and is associated with high morbidity and mortality. Acute Kidney Injury Neutrophil gelatinase–associated lipocalin Evaluation of Symptomatic heart failure Study (AKINESIS) was a prospective, international, multicentre cohort which enrolled 927 patients presenting with acute heart failure (AHF). We hypothesised that novel urinary and plasma cardiorenal biomarkers would predict progression of AKI and associated outcomes in the setting of AHF.
Methods
The primary analysis assessed if biomarkers measured at the time of developing Stage 1 or 2 AKI within 72 hours of admission predicted progression to a higher AKI Stage, RRT or death within 30 days. Twenty-four novel urinary and plasma biomarkers were analysed using commercially available ELISAs and the architect platform.
Results
In total, 175 patients had Stage 1–2 AKI within 72 hours of hospital admission and were included in the study. Of the 24 biomarkers studied, plasma Galectin-3 and EGF improved prediction of AKI progression. None of the other biomarkers were associated with the outcome.
Conclusion
AKI progression in AHF occurred in the absence of tubular damage as assessed by a panel of urinary plasma biomarkers, consistent with the functional mechanism of AKI in AHF. Systemic inflammatory and fibrotic processes may contribute to progression.
Funding
- Government Support – Non-U.S.